Investor Presentaiton

36 Nodal Involvement at Enrollment: Before Pembrolizumab: (10, 2018) Left axillary lymph node core needle biopsy demonstrated squamous cell carcinoma Pembrolizumab (11/2018-1/2019, 4 cycles) discontinued due to autoimmune sequelae After Pembrolizumab: (4, 2019) Left axillary lymph node dissection suggested metastatic squamous cell carcinoma At Enrollment: (9, 2022) Multiple enlarged lymph nodes on imaging, none were eligible as target lesions per RECIST v1.1 Banner, et al. poster 613, ISID 2023 ง ONCONOVA THERAPEUTICS

View entire presentation